Multi-center, prospective, randomized controlled trial
Participants assigned in a 1:1 ratio through the use of sealed envelopes
Researchers were unblinded
Study Period
Drug Administered over 20 minutes
20 minutes of monitoring
24 hours of observation
To detect a absolute risk reduction of 15% from baseline, 302 patient are required
Drug Administered over 20 minutes
20 minutes of monitoring
24 hours of observation
26 Hospitals in Spain
Emergency and Cardiology Departments
Six year recruitment period
Adults with regular wide complex tachycardias
HR≥120, QRS≥120ms
"Good Hemodynamic tolerance"
Systolic BP≥90
No dyspnea at rest
No signs of peripheral hypoperfusion
Lack of severe angina
Age≥18
HR≥120, QRS≥120ms
Systolic BP≥90
No dyspnea at rest
No signs of peripheral hypoperfusion
Lack of severe angina
Age≥18
Treatment with IV procainamide or amiodarone in the previous 24 hours
Poor hemodynamic tolerance
Presence of irregular tachycardia
SVT as determined by physician
Contraindications to the drugs
Patient does not want to participate
PROCAMIO Trial
PART trial
FALLS protocol
ACS - Risk Stratification
STOPP/START criteria
Unstable Angina - NSTEMI Guidelines
Denver screening criteria
Recommendation Grading System